Non-small-cell lung cancer after breast cancer a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women

Journal of Thoracic Oncology

Volumn 9, Issue 8, 2014, Pages 1081-1090

  Milano, Michael T ^a   Strawderman, Robert L ^b   Venigalla, Sriram ^a   Ng, Kimberly ^a   Travis, Lois B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Breast cancer; Lung cancer; Second malignant neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DIAGNOSIS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ESTROGEN RECEPTOR;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; SEER PROGRAM; SURVIVAL RATE;

EID: 84905814941     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000213     Document Type: Article

References (55)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Berry DA, Cronin KA, Plevritis SK, et al.; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-1792.
3. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013;22:561-570.
4. Curtis RE, Freedman DM, Ron E, et al. Chapter 7: new malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E, et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000 National Cancer Institute, NIH Publ No 05-5302. Bethesda, MD; 2006.
5. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Available at: http://seer.cancer.gov/csr/1975-2007/.
6. http://provocativequestions.nci.nih.gov. Accessed January 3, 2014.
7. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005;6:557-565.
8. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952-4960.
9. Hooning MJ, Aleman BM, van Rosmalen AJ, Kuenen MA, Klijn JG, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006;64:1081-1091.
10. Neugut AI, Robinson E, Lee WC, Murray T, Karwoski K, Kutcher GJ. Lung cancer after radiation therapy for breast cancer. Cancer 1993;71:3054-3057.
11. Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 1994;73:1615-1620.
12. Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994;86:983-988.
13. Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. Eur J Cancer 2002;38:1520-1525.
14. Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 2003;97:1404-1411.
15. Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 2003;98:1362-1368.
16. Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 2007;68:359-363.
17. Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007;106:439-451.
18. Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008;26:392-398.
19. Berrington de Gonzalez A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102:220-226.
20. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 2012;104:357-370.
21. Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N. Lung cancer after treatment for breast cancer. Lancet Oncol 2010;11:1184-1192.
22. Massard G, Ducrocq X, Beaufigeau M, et al. Lung cancer following previous extrapulmonary malignancy. Eur J Cardiothorac Surg 2000;18:524-528.
23. Kerendi F, Gal A, Corvera JS, Halkos ME, Miller JI. Characteristics of second primary lung malignancy in patients with known breast cancer. South Med J 2009;102:269-274.
24. Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer 2011;117:5538-5547.
25. Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013;31:930-937.
26. Engert A, Eichenauer DA, Harris NL, et al. Hodgkin Lymphoma. In: Devita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins; 2011:1819-1854.
27. Elena JW, Travis LB, Simonds NI, et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst 2013;105:85-94.
28. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.
29. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012;30:3734-3745.
30. Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289-301.
31. Curtis RE, Freedman DM, Ron E, et al. Chapter 2: methods. In: Curtis RE, Freedman DM, Ron E, et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000 National Cancer Institute, NIH Publ No 05-5302. Bethesda, MD; 2006.
32. Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer 2011;117:5538-5547.
33. Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol 2010;28:5088-5096.
34. Tennis M, Singh B, Hjerpe A, et al. Pathological confirmation of primary lung cancer following breast cancer. Lung Cancer 2010;69:40-45.
35. 2007 multiple primary and histology coding rules. 2013. Available at: http://seer.cancer.gov/tools/mphrules/. Accessed January 8, 2013 .
36. Kosorok MR, Lin C-Y. The versatility of function-indexed weighted logrank statistics. J Am Stat Assoc 1999;94:320-332.
37. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
38. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available at: URL http://www.R-project.org/. Accessed March 1, 2014.
39. AJCC Cancer Staging Manual. Seventh Edition. New York, NY: Springer- Verlag; 2010.
40. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol 2011;29:1885-1892.
41. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-2108.
42. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15:284-290.
43. Behrens C, Travis LB, Wistuba II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev 2000;9:1027-1035.
44. Smith-Bindman R, Miglioretti DL, Johnson E, et al. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. JAMA 2012;307:2400-2409.
45. Bouchardy C, Benhamou S, Schaffar R, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011;117:1288-1295.
46. Schonfeld SJ, Curtis RE, Anderson WF, Berrington de González A. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. Cancer Causes Control 2012;23:1721-1728.
47. Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet 2013;45:345-348.
48. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 2009;20:417-435.
49. Schottenfeld D, Fraumeni JF. Cancer Epidemilogy and Prevention. 2006.
50. Travis LB, Ng AK, Allan JM, et al. Second primary cancers and cardiovascular disease after radiation therapy. NCRP Report No 170. 2012.
51. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987-998.
52. Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in nonsmall cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5:620-630.
53. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
54. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144:33-38.
55. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2011;61:8-30.